公开(公告)号：EP3906232A1

公开(公告)日：2021-11-10

申请号：EP20703096.6

申请日：2020-01-20

申请人： AskAt Inc.

发明人： OKUMURA, Yoshiyuki ,  INAMI, Yukari ,  DROS, Bas ,  LEEMAN, Michel Sebastiaan

IPC分类号： C07D311/58 ,  C07D311/40

公开(公告)号：EP2938607B1

公开(公告)日：2018-09-12

申请号：EP14733062.5

申请日：2014-01-06

申请人： AskAt Inc.

发明人： OKUMURA, Yoshiyuki ,  IWATA, Yasuhiro ,  NUMATA, Toyoharu ,  SUDO, Masaki ,  OKUMURA, Takako

IPC分类号： C07D311/66 ,  A61K31/352 ,  A61P9/00 ,  A61P11/06 ,  A61P17/06 ,  A61P19/00 ,  A61P19/02 ,  A61P19/06 ,  A61P25/00 ,  A61P29/00 ,  A61P35/00 ,  A61P43/00

CPC分类号： C07D311/58 ,  A61K9/4825 ,  C07B2200/13 ,  C07C215/10

摘要： This invention relates to salts and crystal forms of (S)-6-chloro-7-(1,1-dimethylethyl)-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid, Compound A, which is cyclooxygenase-2 inhibitor. The present invention provides a salt of compound A, a crystal form thereof, a process for preparing the said salt and a pharmaceutical composition thereof and its use. The salts and/or co-crystals of Compound A of the present invention show good formulation properties such as high aqueous solubility, good intrinsic dissolution, good crystallinity, good thermal stability or low hygroscopicity.

公开(公告)号：EP3820469A1

公开(公告)日：2021-05-19

申请号：EP19835062.1

申请日：2019-07-11

申请人： Arrys Therapeutics, Inc. ,  AskAt Inc.

发明人： MANFREDI, Mark ,  ECSEDY, Jeffrey ,  CASTRO, Alfredo C. ,  OKUMURA, Yoshiyuki

IPC分类号： A61K31/435 ,  A61K31/4353 ,  A61K31/437 ,  C07D471/00 ,  C07D471/02 ,  C07D471/04

公开(公告)号：EP2938607A1

公开(公告)日：2015-11-04

申请号：EP14733062.5

申请日：2014-01-06

申请人： AskAt Inc.

发明人： OKUMURA, Yoshiyuki ,  IWATA, Yasuhiro ,  NUMATA, Toyoharu ,  SUDO, Masaki ,  OKUMURA, Takako

IPC分类号： C07D311/66 ,  A61K31/352 ,  A61P9/00 ,  A61P11/06 ,  A61P17/06 ,  A61P19/00 ,  A61P19/02 ,  A61P19/06 ,  A61P25/00 ,  A61P29/00 ,  A61P35/00 ,  A61P43/00

CPC分类号： C07D311/58 ,  A61K9/4825 ,  C07B2200/13 ,  C07C215/10

摘要： This invention relates to salts and crystal forms of (S)-6-chloro-7-(1,1-dimethylethyl)-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid, Compound A, which is cyclooxygenase-2 inhibitor. The present invention provides a salt of compound A, a crystal form thereof, a process for preparing the said salt and a pharmaceutical composition thereof and its use. The salts and/or co-crystals of Compound A of the present invention show good formulation properties such as high aqueous solubility, good intrinsic dissolution, good crystallinity, good thermal stability or low hygroscopicity.